These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38427497)

  • 1. Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3.
    Wolfe A; Stimpson G; Ramsey D; Coratti G; Dunaway Young S; Mayhew A; Pane M; Rohwer A; Muni Lofra R; Duong T; O'Reilly E; Milev E; Civitello M; Sansone VA; D'Amico A; Bertini E; Messina S; Bruno C; Albamonte E; Mazzone E; Main M; Montes J; Glanzman AM; Zolkipli-Cunningham Z; Pasternak A; Marini-Bettolo C; Day JW; Darras BT; De Vivo DC; Baranello G; Scoto M; Finkel RS; Mercuri E; Muntoni F;
    J Neuromuscul Dis; 2024; 11(3):665-677. PubMed ID: 38427497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants.
    Stimpson G; Ramsey D; Wolfe A; Mayhew A; Scoto M; Baranello G; Muni Lofra R; Main M; Milev E; Coratti G; Pane M; Sansone V; D'Amico A; Bertini E; Messina S; Bruno C; Albamonte E; Mazzone ES; Montes J; Glanzman AM; Zolkipli-Cunningham Z; Pasternak A; Duong T; Dunaway Young S; Civitello M; Marini-Bettolo C; Day JW; Darras BT; De Vivo DC; Finkel RS; Mercuri E; Muntoni F;
    J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis.
    Hagenacker T; Maggi L; Coratti G; Youn B; Raynaud S; Paradis AD; Mercuri E
    Neurol Ther; 2024 Oct; 13(5):1483-1504. PubMed ID: 39222296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study.
    Coratti G; Bovis F; Pera MC; Scoto M; Montes J; Pasternak A; Mayhew A; Muni-Lofra R; Duong T; Rohwer A; Dunaway Young S; Civitello M; Salmin F; Mizzoni I; Morando S; Pane M; Albamonte E; D'Amico A; Brolatti N; Sframeli M; Marini-Bettolo C; Sansone VA; Bruno C; Messina S; Bertini E; Baranello G; Day J; Darras BT; De Vivo DC; Hirano M; Muntoni F; Finkel R; Mercuri E;
    Eur J Neurol; 2024 Aug; 31(8):e16309. PubMed ID: 38656662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different trajectories in upper limb and gross motor function in spinal muscular atrophy.
    Coratti G; Pera MC; Montes J; Pasternak A; Scoto M; Baranello G; Messina S; Dunaway Young S; Glanzman AM; Duong T; De Sanctis R; Mazzone ES; Milev E; Rohwer A; Civitello M; Pane M; Antonaci L; Frongia AL; Sframeli M; Vita GL; DʼAmico A; Mizzoni I; Albamonte E; Darras BT; Bertini E; Sansone VA; Bovis F; Day J; Bruno C; Muntoni F; De Vivo DC; Finkel R; Mercuri E
    Muscle Nerve; 2021 Nov; 64(5):552-559. PubMed ID: 34327716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.
    Yao X; Peng J; Luo R; Wang X; Lu X; Wu L; Jin R; Zhong J; Liang J; Hong S; Yang L; Zhang X; Mao S; Hu J; Tao Z; Sun D; Wang H; Zhang L; Xia Y; Chen K; Wang Y
    J Neurol; 2024 Aug; 271(8):5378-5391. PubMed ID: 38954034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
    Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool.
    Ramsey D; Scoto M; Mayhew A; Main M; Mazzone ES; Montes J; de Sanctis R; Dunaway Young S; Salazar R; Glanzman AM; Pasternak A; Quigley J; Mirek E; Duong T; Gee R; Civitello M; Tennekoon G; Pane M; Pera MC; Bushby K; Day J; Darras BT; De Vivo D; Finkel R; Mercuri E; Muntoni F
    PLoS One; 2017; 12(2):e0172346. PubMed ID: 28222119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scoliosis Surgery Significantly Impacts Motor Abilities in Higher-functioning Individuals with Spinal Muscular Atrophy1.
    Dunaway Young S; Montes J; Salazar R; Glanzman AM; Pasternak A; Mirek E; Martens W; Finkel RS; Darras BT; De Vivo DC
    J Neuromuscul Dis; 2020; 7(2):183-192. PubMed ID: 32083590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
    Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
    Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy.
    Yeo CJJ; Simeone SD; Townsend EL; Zhang RZ; Swoboda KJ
    J Neuromuscul Dis; 2020; 7(3):257-268. PubMed ID: 32333595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy.
    Pera MC; Coratti G; Bovis F; Pane M; Pasternak A; Montes J; Sansone VA; Dunaway Young S; Duong T; Messina S; Mizzoni I; D'Amico A; Civitello M; Glanzman AM; Bruno C; Salmin F; Morando S; De Sanctis R; Sframeli M; Antonaci L; Frongia AL; Rohwer A; Scoto M; De Vivo DC; Darras BT; Day J; Martens W; Patanella KA; Bertini E; Muntoni F; Finkel R; Mercuri E;
    Ann Clin Transl Neurol; 2021 Aug; 8(8):1622-1634. PubMed ID: 34165911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy.
    Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
    Eur J Neurol; 2022 Dec; 29(12):3666-3675. PubMed ID: 36047967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age and baseline values predict 12 and 24-month functional changes in type 2 SMA.
    Coratti G; Pera MC; Lucibello S; Montes J; Pasternak A; Mayhew A; Glanzman AM; Young SD; Pane M; Scoto M; Messina S; Goemans N; Osorio AN; Pedemonte M; Sansone V; Bertini E; De Vivo DC; Finkel R; Muntoni F; Mercuri E;
    Neuromuscul Disord; 2020 Sep; 30(9):756-764. PubMed ID: 32900576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures.
    Kessler T; Sam G; Wick W; Weiler M
    Eur J Neurol; 2024 Jan; 31(1):e16099. PubMed ID: 37823715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study.
    Trucco F; Ridout D; Scoto M; Coratti G; Main ML; Muni Lofra R; Mayhew AG; Montes J; Pane M; Sansone V; Albamonte E; D'Amico A; Bertini E; Messina S; Bruno C; Parasuraman D; Childs AM; Gowda V; Willis T; Ong M; Marini-Bettolo C; De Vivo DC; Darras BT; Day J; Kichula EA; Mayer OH; Navas Nazario AA; Finkel RS; Mercuri E; Muntoni F;
    Neurology; 2021 Jan; 96(4):e587-e599. PubMed ID: 33067401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nusinersen in adults with type 3 spinal muscular atrophy: long-term outcomes on motor and respiratory function.
    Serrão C; Domingues S; de Campos CF; Moreira S; Conceição I; de Carvalho M; Oliveira Santos M
    Neurol Sci; 2024 Jun; 45(6):2887-2891. PubMed ID: 38589769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.